Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Inhalers pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Inhaler devices deliver medication to the lungs.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Inhalers under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Inhalers and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Inhalers under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
About GlobalData
Introduction
Inhalers Overview
Products under Development
Inhalers - Pipeline Products by Stage of Development
Table Inhalers - Pipeline Products by Stage of Development
Table Inhalers - Pipeline Products by Stage of Development
Inhalers - Pipeline Products by Segment
Table Inhalers - Pipeline Products by Segment
Table Inhalers - Pipeline Products by Segment
Inhalers - Pipeline Products by Territory
Table Inhalers - Pipeline Products by Territory
Table Inhalers - Pipeline Products by Territory
Inhalers - Pipeline Products by Regulatory Path
Table Inhalers - Pipeline Products by Regulatory Path
Table Inhalers - Pipeline Products by Regulatory Path
Inhalers - Pipeline Products by Estimated Approval Date
Table Inhalers - Pipeline Products by Estimated Approval Date
Table Inhalers - Pipeline Products by Estimated Approval Date
Inhalers - Ongoing Clinical Trials
Table Inhalers - Ongoing Clinical Trials
Table Inhalers - Ongoing Clinical Trials
Inhalers - Pipeline Products under Development by Companies
Inhalers Companies - Pipeline Products by Stage of Development
Table Inhalers Companies - Pipeline Products by Stage of Development
Inhalers - Pipeline Products by Stage of Development
Table Inhalers - Pipeline Products by Stage of Development
Table DMC Inhaler - A Phase 1, 2-Part Study in Healthy Male and Female Participants; Part 1 - A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose-Escalation Study of Inhaled DMC-IH1; Part 2 - An Open-Label, 3-Arm Study Assessing the Carryover Effects of Inhaled (DMC-IH1) and Intramuscular (EpiPen) Epinephrine
Table FindAir ONE Smart Inhaler - Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease
Table Iconovo AB - Ongoing Clinical Trials Overview
Table ICOone - A Feasibility Study with Affilogic for the Development of Inhalable Nanofitin-based Biotherapies
Table ICOone - Oxytocin - A Randomized, Single-Center, Partially Single-Blind Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Single and Repeated Doses of Oxytocin Administered via Inhalation or Intravenous or Intramuscular Administration in Healthy Female Participants
Table Afrezza Inhaler - INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined with Insulin Degludec Versus Usual Care in Adults with Type 1 Diabetes
North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
Table North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
Table Smart Inhaler System - Product Status
Table Smart Inhaler System - Product Description
Novartis AG Company Overview
Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
Table Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
Table Atectura Breezhaler - Product Status
Table Atectura Breezhaler - Product Description
Table Enerzair Breezhaler - Product Status
Table Enerzair Breezhaler - Product Description
Table Next Generation Breezhaler Inhaler - Product Status
Table Next Generation Breezhaler Inhaler - Product Description
Table Novartis AG - Ongoing Clinical Trials Overview
Table Enerzair Breezhaler - A 24-week Prospective, Open-label, Multicenter, Single-arm, Observational Regulatory Post-Marketing Surveillance (rPMS) Study in Real-world Setting (Mandatory by Local HA Regulation) for Enerzair (QVM149 150/50/80 ìg o.d. and QVM149 150/50/160 ìg o.d. Via Breezhaler)
Table Enerzair Breezhaler - A Double-dummy, Double-blind, Randomized, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Table Enerzair Breezhaler - Comparison of Enerziar and Trelegy, Single Inhaler Triple Therapy (SITT), in Asthma
Table Atectura Breezhaler - A 24-week Prospective, Open-label, Multicenter, Single-arm Regulatory Post-Marketing Surveillance (rPMS) Study in Real-world Setting (Mandatory by Local HA Regulation) for Atectura (QMF149 150/80 ìg o.d., QMF149 150/160 ìg o.d. and QMF149 150/320 ìg o.d. Via Breezhaler)
Table Atectura Breezhaler - A Double-dummy, Double-blind, Randomized, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Table ProAir Digihaler - Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma
Table AirDuo Digihaler - Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma
Transpire Bio Inc Company Overview
Transpire Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
Table United Therapeutics Corp - Ongoing Clinical Trials Overview
Table Tyvaso DPI - A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)
Table Tyvaso DPI - A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
Table Tyvaso DPI - An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
University of Kansas Company Overview
University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
Table University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
Table Dry Powder Inhaler - Product Status
Table Dry Powder Inhaler - Product Description
University of Sydney Company Overview
University of Sydney Pipeline Products & Ongoing Clinical Trials Overview
Table University of Sydney Pipeline Products & Ongoing Clinical Trials Overview
Table Dry Powder Inhaler - Product Status
Table Dry Powder Inhaler - Product Description
University of Texas Medical Branch at Galveston Company Overview
University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
Table University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
Table Dry Powder Drug Delivery System - Product Status
Table Dry Powder Drug Delivery System - Product Description
Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
Table Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
Table Drug Delivery Device - Cystic Fibrosis - Product Status
Table Drug Delivery Device - Cystic Fibrosis - Product Description
Table Dry Powder Inhaler - Product Status
Table Dry Powder Inhaler - Product Description
Inhalers- Recent Developments
Jun 01, 2024: Boehringer Ingelheim's COPD and Asthma Inhalers Are Now Available for $35 a Month for Eligible Patients
May 24, 2024: Iconovo Publishes the Annual Report 2023
May 15, 2024: Cipla UPS Investment in Point-Of-Care Testing Firm Achira Labs
May 13, 2024: Novo Nordisk Plans Bond Sale to Fund Expansion
May 09, 2024: Nektar Therapeutics Reports First Quarter 2024 Financial Results
May 08, 2024: Teva Pharmaceutical Industries Reports Earnings Results for the First Quarter Ended March 31, 2024
May 06, 2024: Iconovo Receives Patent Protection for Icores in China
May 02, 2024: Novo Nordisk's Sales Increased by 22% in Danish kroner and by 24% at Constant Exchange Rates to DKK 65.3 billion in the First Three Months of 2024
May 01, 2024: MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
Apr 30, 2024: 3M First-Quarter Results Driven by Strong Operational Performance; Company Initiates Full-Year 2024 Guidance Reflecting Completion of Solventum Spin
Apr 16, 2024: Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone
Apr 11, 2024: Orion publishes Interim Report for January–March 2024 and Holds a Webcast on 25 April 2024
Apr 09, 2024: Swiss Pharma Company Novartis to Lay Off 680 Employees from Switzerland and USA Offices in Next 2-3 Years
Apr 03, 2024: Adherium Partners with Rimidi to Revolutionise Respiratory Clinical Management Solutions
Mar 18, 2024: Astrazeneca Caps Patient Out-Of-Pocket Costs at $35 per Month for its US Inhaled Respiratory Portfolio
Mar 15, 2024: Cipla Announces Appointment of Senior Management
Mar 13, 2024: 3M Names New CEO Amid PFAS Battles, Health Spinoff
Mar 12, 2024: 3M Announces New Leadership Appointments
Mar 11, 2024: Iconovo to Present Positive Data From a Feasibility Study on Nanofitins in ICOone
Mar 05, 2024: United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
Mar 04, 2024: Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
Feb 27, 2024: MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Feb 20, 2024: MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
Feb 08, 2024: Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
Feb 07, 2024: Iconovo Signs Additional Contract with Kiox Pharma for Development of a New Inhalable Treatment for Interstitial Lung Disease
Feb 06, 2024: Iconovo Launches Improved Versions of Nasal Icoone Inhalers
Feb 01, 2024: Qualcomm Reports Q1 Fiscal 2024 Results
Feb 01, 2024: Iconovo Receives Order From Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler
Jan 31, 2024: Savara to Present at Two Upcoming Healthcare Conferences
Jan 31, 2024: Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
Jan 31, 2024: Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
Jan 23, 2024: Orion Group Announces Executive Management Board
Jan 23, 2024: 3M Delivers Strong Fourth-Quarter Results; Improves Operational Performance and Exceeds Earnings and Cash Flow Expectations
Jan 16, 2024: 3M Picks Former NuVasive CEO as President of Medical Solutions
Jan 15, 2024: Hassan Fahmi Appointed as Managing Director of GSK Egypt
Jan 08, 2024: Iconovo Recruits Gary Pitcairn PhD as Senior Scientific Advisor
Dec 04, 2023: Adherium Commences Production and US Market Release of Advanced Teva pMDI Compatible Smartinhaler
Dec 04, 2023: Aptar Awarded US FDA Contract to Study Opportunities for Low Global Warming Potential Propellants for Metered Dose Inhalers
Nov 09, 2023: 3M Announces Leadership Changes
Nov 07, 2023: Tom Sweet Elected to 3M Board of Directors
Nov 07, 2023: Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
Nov 06, 2023: Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA
Nov 02, 2023: Qualcomm Reports Q4 and Fiscal 2023 Results
Oct 31, 2023: United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis
Oct 27, 2023: Cipla Announces Unaudited Consolidated Financial Results for Quarter Ended September 30th, 2023
Oct 24, 2023: 3M Reports Third Quarter 2023 Results; Company Increases Full Year Adjusted Earnings and Cash Flow Expectations
Oct 19, 2023: DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
Oct 16, 2023: Orion publishes Interim Report for January–September 2023 on Thursday 26 October 2023
Oct 15, 2023: Qualcomm To Layoff 1,258 Employees In Two Locations, Experts State That U.S. Efforts To Suppress China Backfired And Is Affecting Firms
Oct 13, 2023: Qualcomm to Lay Off 1,258 Employees in California
Oct 12, 2023: Qualcomm to Cut Roughly 1258 Jobs in California
Oct 03, 2023: Nemera reinforces commitment to sustainability with first integrated ESG report
Sep 28, 2023: Teva Announces Changes to Executive Management Team
Sep 25, 2023: Nemera Announces Commitment to sustainability
Sep 10, 2023: Nemera extends manufacturing capabilities in North America
Sep 05, 2023: MannKind Announces Participation at Upcoming Conferences
Aug 28, 2023: Novartis to Let Go 100 Employees in Latest Round of Layoffs
Aug 23, 2023: 3M Appoints Carrie Cox as Chairman of the Board of Directors of the Independent Health Care Company
Aug 22, 2023: Bryan Hanson Named CEO of 3M's Health Care Business Group
Aug 18, 2023: Qualcomm to Reportedly Cut 200 Jobs in Taiwan
Aug 17, 2023: Iconovo Receives Additional Development Contract From Kiox Pharma For New Inhalable Treatment Against Rare Disease
Aug 17, 2023: Ziccum to present at Investor Conference BioFuture 2023 in New York
Aug 11, 2023: Audrey Choi elected to 3M Board of Directors
Aug 03, 2023: Qualcomm Announces Third Quarter Fiscal 2023 Results
Aug 01, 2023: MannKind Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
Jul 31, 2023: Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
Jul 31, 2023: MannKind to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023